Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Response

Published

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Granger, CB; Mahaffey, KW; Weaver, WD; Theroux, P; Hochman, JS; Filloon, TG; Todaro, TG; Rollins, S; Mojcik, CF; Nicolau, JC; Ruzyllo, W; Armstrong, PW

Published Date

  • April 27, 2004

Published In

Volume / Issue

  • 109 / 16

Start / End Page

  • E195 - E196

Published By

Pages

  • 2

International Standard Serial Number (ISSN)

  • 0009-7322

Language

  • English